August 2025's Promising Penny Stocks In Global Market

As global markets navigate a landscape marked by interest rate adjustments and shifting trade dynamics, investors are keenly observing the opportunities that arise amidst these changes. Penny stocks, often seen as relics of earlier market days, still hold relevance by offering exposure to smaller or newer companies with potential for growth. By identifying those with strong financials and promising outlooks, investors can find compelling opportunities in this segment of the market.

Top 10 Penny Stocks Globally

Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$2.39 A$109.91M ★★★★★★ Lever Style (SEHK:1346) HK$1.47 HK$915.41M ★★★★★★ GTN (ASX:GTN) A$0.405 A$74.36M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.49 HK$2.1B ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ★★★★★★ MGB Berhad (KLSE:MGB) MYR0.505 MYR298.78M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.88 SGD11.33B ★★★★★☆ Zetrix AI Berhad (KLSE:ZETRIX) MYR0.90 MYR6.92B ★★★★★☆ Begbies Traynor Group (AIM:BEG) £1.155 £183.58M ★★★★★★ Netgem (ENXTPA:ALNTG) €0.934 €31.5M ★★★★★★

Click here to see the full list of 3,784 stocks from our Global Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Goldpac Group

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Goldpac Group Limited is an investment holding company that offers embedded software, secure payment products, and smart financial self-service kiosks in Mainland China and internationally, with a market cap of HK$918.61 million.

Operations: The company's revenue is derived from two main segments: Platform and Service, generating CN¥472.94 million, and Embedded Software and Secure Payment Products, contributing CN¥622.36 million.

Market Cap: HK$918.61M

Goldpac Group Limited, with a market cap of HK$918.61 million, is experiencing challenges as its revenue and profit are expected to decline by 10%-20% and 20%-30% respectively for the first half of 2025 compared to the previous year. Despite being debt-free and having high-quality earnings, the company's return on equity is low at 2.5%, and its profit margins have decreased from last year's figures. The management team is experienced with an average tenure of nine years, but recent board changes may impact strategic direction. The stock trades significantly below estimated fair value but faces unstable dividend records.

Dive into the specifics of Goldpac Group here with our thorough balance sheet health report. Assess Goldpac Group's previous results with our detailed historical performance reports.SEHK:3315 Revenue & Expenses Breakdown as at Aug 2025

ValueMax Group

Simply Wall St Financial Health Rating: ★★★★☆☆

Story Continues

Overview: ValueMax Group Limited, with a market cap of SGD729.63 million, operates in Singapore focusing on pawnbroking, moneylending, jewelry and watches retailing, and gold trading businesses.

Operations: There are no specific revenue segments reported for the company.

Market Cap: SGD729.63M

ValueMax Group Limited, with a market cap of SGD729.63 million, reported strong half-year earnings growth, with sales reaching SGD 268.34 million and net income at SGD 48.03 million, both up from the previous year. Despite high-quality earnings and improved profit margins (19.3%), the company's operating cash flow remains negative, impacting debt coverage and dividend sustainability (3.44%). While its short-term assets significantly exceed liabilities, indicating solid liquidity management, ValueMax's net debt to equity ratio is high at 126.2%. The stock trades below fair value estimates but benefits from experienced management and board teams.

Take a closer look at ValueMax Group's potential here in our financial health report. Learn about ValueMax Group's historical performance here.SGX:T6I Debt to Equity History and Analysis as at Aug 2025

Huapont Life SciencesLtd

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Huapont Life Sciences Co., Ltd. operates in the fields of medicine, medical care, agrochemicals, new materials, and tourism both in China and internationally with a market cap of CN¥8.74 billion.

Operations: Huapont Life Sciences Co., Ltd. has not reported specific revenue segments, but it operates across various sectors including medicine, medical care, agrochemicals, new materials, and tourism both domestically and internationally.

Market Cap: CN¥8.74B

Huapont Life Sciences Co., Ltd., with a market cap of CN¥8.74 billion, operates across diverse sectors but remains unprofitable, facing challenges in earnings growth and profitability. The management team is experienced, with an average tenure of 11.6 years, and the board also brings seasoned expertise. Despite its financial struggles, the company has managed to reduce its debt to equity ratio from 82.6% to 59.7% over five years and maintains satisfactory net debt levels at 31.6%. Recent changes include amendments to company bylaws and the election of Zhang Songshan as a non-independent director.

Get an in-depth perspective on Huapont Life SciencesLtd's performance by reading our balance sheet health report here. Understand Huapont Life SciencesLtd's track record by examining our performance history report.SZSE:002004 Revenue & Expenses Breakdown as at Aug 2025

Seize The Opportunity

Gain an insight into the universe of 3,784 Global Penny Stocks by clicking here. Searching for a Fresh Perspective? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:3315 SGX:T6I and SZSE:002004.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments